المؤلفون: В. А. Чубенко, М. Б. Бычков, Н. В. Деньгина, А. Е. Кузьминов, Д. Д. Сакаева, А. И. Семенова

المصدر: Malignant tumours; Том 14, № 3s2-1 (2024); 105-114 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 105-114 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лучевая терапия, локализованный мелкоклеточный рак легкого, распространенный мелкоклеточный рак легкого, химиотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1360/966; https://www.malignanttumors.org/jour/article/view/1360

الاتاحة: https://www.malignanttumors.org/jour/article/view/1360
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-05

المؤلفون: К. К. Лактионов, Е. В. Артамонова, В. В. Бредер, В. А. Горбунова, И. А. Демидова, Н. В. Деньгина, Ф. В. Моисеенко, Е. В. Реутова, Д. Д. Сакаева, А. И. Семенова, А. В. Смолин, Д. Л. Строяковский, М. В. Черных

المصدر: Malignant tumours; Том 14, № 3s2-1 (2024); 65-104 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 65-104 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: экспрессия PD-L1, аденокарцинома, неплоскоклеточный рак легкого, плоскоклеточный рак легкого, активирующие мутации

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1359/965; https://www.malignanttumors.org/jour/article/view/1359

الاتاحة: https://www.malignanttumors.org/jour/article/view/1359
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-04

المؤلفون: А. А. Трякин, Н. С. Бесова, Н. М. Волков, О. А. Гладков, В. В. Карасева, Д. Д. Сакаева, Н. В. Фадеева, М. Ю. Федянин

المصدر: Malignant tumours; Том 14, № 3s2-1 (2024); 33-46 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 33-46 ; 2587-6813 ; 2224-5057

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1357/963; https://www.malignanttumors.org/jour/article/view/1357

الاتاحة: https://www.malignanttumors.org/jour/article/view/1357
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-01

المؤلفون: T. T. Tikhomirova, A. S. Tyulyandina, A. A. Rumyantsev, E. R. Israelyan, T. V. Kekeeva, O. V. Vedrova, M. L. Filipenko, L. N. Lyubchenko, I. A. Demidova, E. N. Imyanitov, S. Y. Andreev, S. V. Khokhlova, V. V. Saevets, G. B. Statsenko, L. A. Kolomiets, S. A. Tkachenko, I. A. Koroleva, A. S. Lisyanskaya, O. A. Bakashvili, L. I. Krikunova, E. P. Solovieva, D. M. Ponomarenko, L. Y. Vladimirova, S. E. Krasilnikov, V. B. Shirinkin, D. D. Sakaeva, E. A. Rumyantseva, S. A. Emeliyanov, D. L. Stroyakovskiy, E. G. Novikova, E. A. Ronina, V. I. Vladimirov, O. Y. Novikova, L. S. Zagumennova, V. V. Gorobtsova, E. V. Cherepanova, E. N. Pashkova, V. M. Moiseyenko, F. G. Ivanova, D. P. Udovitsa, V. V. Karaseva, S. A. Tyulyandin, Т. Е. Тихомирова, А. С. Тюляндина, А. А. Румянцев, Э. Р. Исраелян, Т. В. Кекеева, О. В. Ведрова, М. Л. Филипенко, Л. Н. Любченко, И. А. Демидова, Е. Н. Имянитов, С. Ю. Андреев, С. В. Хохлова, В. В. Саевец, Г. Б. Стаценко, Л. А. Коломиец, С. А. Ткаченко, И. А. Королева, А. С. Лисянская, О. А. Бакашвили, Л. И. Крикунова, Е. П. Соловьева, Д. М. Пономаренко, Л. Ю. Владимирова, С. Э. Красильников, В. Б. Ширинкин, Д. Д. Сакаева, Е. А. Румянцева, С. А. Емельянов, Д. Л. Строяковский, Е. Г. Новикова, Е. А. Ронина, В. И. Владимиров, О. Ю. Новикова, Л. С. Загуменнова, В. В. Горобцова, Е. В. Черепанова, Е. Н. Пашкова, В. М. Моисеенко, Ф. Г. Иванова, Д. П. Удовица, В. В. Карасева, С. А. Тюляндин

المصدر: Malignant tumours; Том 13, № 4 (2023); 46-59 ; Злокачественные опухоли; Том 13, № 4 (2023); 46-59 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: молекулярно-генетическое тестирование, BRCA1 / 2 mutations, molecular genetic testing, мутации в генах BRCA1/2

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1275/913; International Agency for Research on Cancer Global Cancer Observatory : Cancer Today. [(accessed on 5 June 2022)]; Available online: https://gco.iarc.fr/today/online-analysis-table [Ref list].; American Cancer Society Key Statistics for Ovarian Cancer. [(accessed on 5 June 2022)]. Available online: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html [Ref list].; Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, et al. Hereditary Ovarian Cancer : Towards a Cost-Effective Prevention Strategy. Int J Environ Res Public Health. 2022 Sep 23; 19 (19) : 12057. doi:10.3390/ijerph191912057. PMID : 36231355; PMCID : PMC9565024.; Hinchcliff E.M., Bednar E., Lu K.H., Rauh-Hain J.A. Disparities in gynecologic cancer genetics evaluation. Gynecol. Oncol. 2019; 153 : 184–191. doi:10.1016/j.ygyno.2019.01.024.; Kanchi K.L., Johnson K.J., Lu C., McLellan M.D., Leiserson M.D.M., Wendl M.C., et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat. Commun. 2014; 5 : 3156. doi:10.1038/ncomms4156.; Biglia N., Sgandurra P., Bounous V.E., Maggiorotto F., Piva E., Pivetta E., et al. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers : Analysis of prognostic factors and survival. Ecancermedicalscience. 2016; 10 : 639. doi:10.3332/ecancer.2016.639.; Hunn J., Rodriguez G.C. Ovarian cancer : Etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol. 2012; 55 : 3–23. doi:10.1097/GRF.0b013e31824b4611.; Andrews L, Mutch DG. Hereditary Ovarian Cancer and Risk Reduction. Best Pract Res Clin Obstet Gynaecol. 2017 May; 41 : 31–48. doi:10.1016/j.bpobgyn.2016.10.017. Epub 2017 Jan 17. PMID : 28254144.; Любченко Л. Н., Батенева Е. И. Медико-генетическое консультирование и ДНК-диагностика при наследственной предрасположенности к раку молочной железы и раку яичников .– м. : иг РОНЦ, 2014.; Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer : a report from the Australian Ovarian Cancer Study Group. [Erratum appears in J Clin Oncol. 2012 Nov 20; 30 (33) : 4180]. Journal of Clinical Oncology 2012.30 (21) : 2654–63.; Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012.307 (4) : 382–90.; Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Wholegenome characterization of chemoresistant ovarian cancer. Nature 2015.521 (7553) : 489–94.; https://www.malignanttumors.org/jour/article/view/1275

الاتاحة: https://www.malignanttumors.org/jour/article/view/1275
https://doi.org/10.18027/2224-5057-2023-13-4-46-59

المؤلفون: E. V. Karabina, D. D. Sakaeva, O. N. Lipatov, Е. В. Карабина, Д. Д. Сакаева, О. Н. Липатов

المصدر: Creative surgery and oncology; Том 14, № 1 (2024); 69-77 ; Креативная хирургия и онкология; Том 14, № 1 (2024); 69-77 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: нежелательные явления, malignancies, antineoplastic drug therapy, oncology, efficacy of off-label use, adverse events, злокачественные новообразования, противоопухолевая лекарственная терапия, онкология, эффективность использования off-label

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/918/593; Scher K.S., Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17):2036–8. DOI:10.1200/JCO.2012.41.6727; Марцевич С.Ю., Навасардян А.Р., Комкова Н.А. Назначение лекарственных средств не в соответствии с официальной инструкцией по медицинскому применению (off-label). Возможные причины, виды и последствия. Правовое регулирование в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2017;13(5):667–74. DOI:10.20996/1819-6446-2017-13-5-667-674; Переверзев А.П., Лепахин В.К. Современный взгляд на проблему применения ЛС с нарушением предписаний инструкции. Медицинский совет 2013;(4-1):110–1. DOI:10.21518/2079-701X-2013-4-110-111; Lim M., Shulman D.S., Roberts H., Li A., Clymer J., Bona K., et al. Offlabel prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020;9(18):6658–66. DOI:10.1002/cam4.3349; Lee D.P., Skolnik J.M., Adamson P.C. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol. 2005;23(33):8431–41. DOI:10.1200/JCO.2005.02.1568; Aguilera D., Mazewski C., Fangusaro J., MacDonald T.J., McNallKnapp R.Y., Hayes L.L., et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multiinstitutional experience. Childs Nerv Syst. 2013;29(4):589–96. DOI:10.1007/s00381-012-2013-4; Spini A., Ciccone V., Rosellini P., Ziche M., Lucenteforte E., Salvo F., et al. Safety of anti-angiogenic drugs in pediatric patients with solid tumors: a systematic review and meta-analysis. Cancers (Basel). 2022;14(21):5315. DOI:10.3390/cancers14215315; Kalra M., Heath J.A., Kellie S.J., Dalla Pozza L., Stevens M.M., Swamy S., et al. Confirmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma. J Pediatr Hematol Oncol. 2015;37(6):e341–6. DOI:10.1097/MPH.0000000000000371; Calò P., Pianton N., Basle A., Vasiljevic A., Barritault M., Beuriat P.A., et al. Bevacizumab as single agent in children and teenagers with optic pathway glioma. Cancers (Basel). 2023;15(4):1036. DOI:10.3390/cancers15041036; Green K., Panagopoulou P., D’Arco F., O’Hare P., Bowman R., Walters B., et al. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes. Neuro Oncol. 2023;25(4):774–85. DOI:10.1093/neuonc/noac223; Bennebroek C.A.M., van Zwol J., Porro G.L., Oostenbrink R., Dittrich A.T.M., Groot A.L.W., et al. Impact of bevacizumab on visual function, tumor size, and toxicity in pediatric progressive optic pathway glioma: a retrospective nationwide multicentre study. Cancers (Basel). 2022;14(24):6087. DOI:10.3390/cancers14246087; Cenna R., Basiricò M., Berchialla P., Bertorello N., Cagnazzo C., et al. Off-label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center. Pediatr Blood Cancer. 2023;70(3):e30148. DOI:10.1002/pbc.30148; de Marcellus C., Tauziède-Espariat A., Cuinet A., Pasqualini C., Robert M.P., Beccaria K., et al. The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. J Neurooncol. 2022;157(2):355–64. DOI:10.1007/s11060-022-03970-4; El-Khouly F.E., Veldhuijzen van Zanten S.E.M., Jansen M.H.A., Bakker D.P., Sanchez Aliaga E., Hendrikse N.H., et al. A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. J Neurooncol. 2021;153(2):263–71. DOI:10.1007/s11060-021-03763-1; Su J.M., Murray J.C., McNall-Knapp R.Y., Bowers D.C., Shah S., Adesina A.M., et al. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatr Blood Cancer. 2020;67(6):e28283. DOI:10.1002/pbc.28283; Crotty E.E., Leary S.E.S., Geyer J.R., Olson J.M., Millard N.E., Sato A.A., et al. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience. J Neurooncol. 2020;148(3):607–17. DOI:10.1007/s11060-020-03558-w; Zhukova N., Rajagopal R., Lam A., Coleman L., Shipman P., Walwyn T., et al. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. Cancer Med. 2019;8(1):40–50. DOI:10.1002/cam4.1799; Metts J., Harrington B., Salman E., Bradfield S.M., Flanary J., Mosha M., et al. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors. Childs Nerv Syst. 2022;38(5):919–28. DOI:10.1007/s00381-022-05479-7; Schiavetti A., Varrasso G., Mollace M.G., Dominici C., Ferrara E., Papoff P., et al. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience. Childs Nerv Syst. 2019;35(6):1007–12. DOI:10.1007/s00381-019-04117-z; Levy A.S., Krailo M., Chi S., Villaluna D., Springer L., Williams-Hughes C., et al. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. 2021;68(8):e29031. DOI:10.1002/pbc.29031; Gaspar N., Campbell-Hewson Q., Gallego Melcon S., Locatelli F., Venkatramani R., Hecker-Nolting S., et al. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆. ESMO Open. 2021;6(5):100250. DOI:10.1016/j.esmoop.2021.100250; Gaspar N., Venkatramani R., Hecker-Nolting S., Melcon S.G., Locatelli F., Bautista F., et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021;22(9):1312–21. DOI:10.1016/S1470-2045(21)00387-9; Mascarenhas L., Chi Y.Y., Hingorani P., Anderson J.R., Lyden E.R., Rodeberg D.A., et al. Randomized phase II trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol. 2019;37(31):2866–74. DOI:10.1200/JCO.19.00576; Russo I., Di Paolo V., Crocoli A., Mastronuzzi A., Serra A., Di Paolo P.L., et al. A chart review on the feasibility and safety of the vincristine irinotecan pazopanib (VIPaz) association in children and adolescents with resistant or relapsed sarcomas. Front Oncol. 2020;10:1228. DOI:10.3389/fonc.2020.01228; Weiss A.R., Chen Y.L., Scharschmidt T.J., Chi Y.Y., Tian J., Black J.O., et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(8):1110–22. DOI:10.1016/S1470-2045(20)30325-9; Federico S.M., Caldwell K.J., McCarville M.B., Daryani V.M., Stewart C.F., Mao S., et al. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours. Eur J Cancer. 2020;132:35–42. DOI:10.1016/j.ejca.2020.03.010; Geoerger B., Morland B., Jiménez I., Frappaz D., Pearson A.D.J., Vassal G., et al. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. Eur J Cancer. 2021;153:142–52. DOI:10.1016/j.ejca.2021.05.023; Meany H.J., Widemann B.C., Hinds P.S., Bagatell R., Shusterman S., Stern E., et al. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021;68(11):e29282. DOI:10.1002/pbc.29282; Santana V.M., Sahr N., Tatevossian R.G., Jia S., Campagne O., Sykes A., et al. A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors. Cancer. 2020;126(8):1749–57. DOI:10.1002/cncr.32722; Inaba H., Panetta J.C., Pounds S.B., Wang L., Li L., Navid F., et al. Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory/relapsed leukemia or solid tumor malignancies. Clin Cancer Res. 2019;25(24):7320–30. DOI:10.1158/1078-0432.CCR-19-0470; Glod J., Arnaldez F.I., Wiener L., Spencer M., Killian J.K., Meltzer P., et al. A phase II trial of vandetanib in children and adults with succinate dehydrogenase-deficient gastrointestinal stromal tumor. Clin Cancer Res. 2019;25(21):6302–8. DOI:10.1158/1078-0432.CCR-19-0986; Verschuur A.C., Bajčiová V., Mascarenhas L., Khosravan R., Lin X., Ingrosso A., et al. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. Cancer Chemother Pharmacol. 2019;84(1):41–50. DOI:10.1007/s00280-019-03814-5; Keino D., Yokosuka T., Hirose A., Sakurai Y., Nakamura W., Fujita S., et al. Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study). Pediatr Blood Cancer. 2020;67(11):e28655. DOI:10.1002/pbc.28655; Kraft I.L., Akshintala S., Zhu Y., Lei H., Derse-Anthony C., Dombi E., et al. Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib. clin cancer res. 2018;24(4):753–65. DOI:10.1158/1078-0432.CCR-17-2101; Raciborska A., Bilska K. Sorafenib in patients with progressed and refractory bone tumors. Med Oncol. 2018;35(10):126. DOI:10.1007/s12032-018-1180-x; Modak S., Kushner B.H., Basu E., Roberts S.S., Cheung N.K. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatr Blood Cancer. 2017;64(8):10.1002/pbc.26448. DOI:10.1002/pbc.26448; Wetmore C., Daryani V.M., Billups C.A., Boyett J.M., Leary S., Tanos R., et al. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children’s Oncology Group Study ACNS1021. Cancer Med. 2016;5(7):1416–24. DOI:10.1002/cam4.713; Mascolo A., Scavone C., Bertini M., Brusco S., Punzo F., Pota E., et al. Safety of anticancer agents used in children: a focus on their off-label use through data from the spontaneous reporting system. Front Pharmacol. 2020;11:621. DOI:10.3389/fphar.2020.00621; Eaton A.A., Sima C.S., Panageas K.S. Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-Medicare Data. J Natl Compr Canc Netw. 2016;14(1):57–65. DOI:10.6004/jnccn.2016.0007; Dal Pan G.J. Monitoring the safety of medicines used off-label. Clin Pharmacol Ther. 2012;91:787–95. DOI:10.1038/clpt.2012.24; Rusz C.M., Ősz B.E., Jîtcă G., Miklos A., Bătrînu M.G., Imre S. Offlabel medication: from a simple concept to complex practical aspects. Int J Environ Res Public Health. 2021;18(19):10447. DOI:10.3390/ijerph181910447; Eguale T., Buckeridge D.L., Verma A., Winslade N.E., Benedetti A., Hanley J.A., et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55–63. DOI:10.1001/jamainternmed.2015.6058; https://www.surgonco.ru/jour/article/view/918

الاتاحة: https://www.surgonco.ru/jour/article/view/918
https://doi.org/10.24060/2076-3093-2024-14-1-69-77

المؤلفون: О. В. Сомонова, Э. А. Антух, А. В. Варданян, Е. Г. Громова, Б. И. Долгушин, А. Л. Елизарова, Д. Д. Сакаева, В. Ю. Сельчук, А. А. Трякин, В. А. Черкасов

المصدر: Malignant tumours; Том 13, № 3s2-2 (2023); 167-178 ; Злокачественные опухоли; Том 13, № 3s2-2 (2023); 167-178 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: прямые оральные антикоагулянты, тромбоэмболические осложнения, низкомолекулярные гепарины, гепарин натрия, фондапаринукс

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1254/888; https://www.malignanttumors.org/jour/article/view/1254

الاتاحة: https://www.malignanttumors.org/jour/article/view/1254
https://doi.org/10.18027/2224-5057-2023-13-3s2-2-167-178

المؤلفون: В. А. Чубенко, М. Б. Бычков, Н. В. Деньгина, А. Е. Кузьминов, Д. Д. Сакаева, А. И. Семенова

المصدر: Malignant tumours; Том 13, № 3s2-1 (2023); 66-71 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 66-71 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лучевая терапия, локализованный мелкоклеточный рак легкого, распространенный мелкоклеточный рак легкого, химиотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1203/838; https://www.malignanttumors.org/jour/article/view/1203

الاتاحة: https://www.malignanttumors.org/jour/article/view/1203
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-66-71

المؤلفون: К. К. Лактионов, Е. В. Артамонова, В. В. Бредер, В. А. Горбунова, И. А. Демидова, Н. В. Деньгина, Ф. В. Моисеенко, С. А. Проценко, Е. В. Реутова, Д. Д. Сакаева, А. В. Смолин, Д. Л. Строяковский, М. Д. Тер-Ованесов, М. В. Черных

المصدر: Malignant tumours; Том 13, № 3s2-1 (2023); 42-65 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 42-65 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: ROS1, аденокарцинома, неплоскоклеточный рак легкого, плоскоклеточный рак легкого, мутация EGFR, транслокация ALK

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1202/837; https://www.malignanttumors.org/jour/article/view/1202

الاتاحة: https://www.malignanttumors.org/jour/article/view/1202
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-42-65

المؤلفون: А. А. Трякин, Н. С. Бесова, Н. М. Волков, О. А. Гладков, В. В. Карасева, Д. Д. Сакаева, Н. В. Фадеева, М. Ю. Федянин

المصدر: Malignant tumours; Том 13, № 3s2-1 (2023); 28-41 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 28-41 ; 2587-6813 ; 2224-5057

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1201/836; https://www.malignanttumors.org/jour/article/view/1201

الاتاحة: https://www.malignanttumors.org/jour/article/view/1201
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-28-41

المؤلفون: E. V. Karabina, D. D. Sakaeva, O. N. Lipatov, Е. В. Карабина, Д. Д. Сакаева, О. Н. Липатов

المساهمون: This work is not funded, Данная работа не финансировалась

المصدر: Creative surgery and oncology; Том 13, № 2 (2023); 151-158 ; Креативная хирургия и онкология; Том 13, № 2 (2023); 151-158 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: эффективность использования off-label, malignancy, anticancer drug therapy, oncology, efficacy of off-label use, злокачественные новообразования, противоопухолевая лекарственная терапия, онкология

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/812/549; Saiyed M. M., Ong P. S., Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Th er. 2017; 42 (3): 251–8. DOI:10.1111/jcpt.12507; Joerger M., Schaer-Thuer C., Koeberle D., Matter-Walstra K., Gibbons-Marsico J., Diem S., et al. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol. 2014; 70 (6): 719–25. DOI:10.1007/s00228-014-1662-5; Herbrand A. K., Schmitt A. M., Briel M., Ewald H., Goldkuhle M., Diem S., et al. Association of supporting trial evidence and reimbursement for off-label use of cancer drugs. JAMA Netw Open. 2021; 4 (3): e210380. DOI:10.1001/jamanetworkopen.2021.0380; Kurzrock R., Gurski L. A., Carlson R. W., Ettinger D. S., Horwitz S. M., Kumar S. K., et al. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019; 30 (10): 1647–52. DOI:10.1093/annonc/mdz232; Wei G., Wu M., Zhu H., Han S., Chen J., Zhai C., et al. Label use of antineoplastic drugs to treat malignancies: evidence from China based on a nationwide medical insurance data analysis. Front Pharmacol. 2021; 12: 616453. DOI:10.3389/fphar.2021.616453; Mellor J. D., Van Koeverden P., Yip S. W., Thakerar A., Kirsa S. W., Michael M. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme. Intern Med J. 2012; 42 (11): 1224–9. DOI:10.1111/j.1445-5994.2012.02751.x.; Kalis J. A., Pence S. J., Mancini R. S., Zuckerman D. S., Ineck J. R. Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract. 2015; 11 (2): e139–43. DOI:10.1200/JOP.2014.001354; Bun S., Yonemori K., Sunadoi H., Nishigaki R., Noguchi E., Okusaka T., et al. Safety and evidence of off-label use of approved drugs at the national cancer center hospital in Japan. JCO Oncol Pract. 2021; 17 (3): e416–25. DOI:10.1200/OP.20.00131; de Vries E. G. E., Cherny N. I., Voest E. E. When is off-label off-road? Ann Oncol. 2019; 30 (10): 1536–8. DOI:10.1093/annonc/mdz445; Rauh S., Mavroeidis L., Ntellas P., Gazouli I., Gkoura S., Papadaki A., et al. Old drug, new clinical use, no man’s land for the indication: an awareness call from European experts. ESMO Open. 2020; 5 (1): e000615. DOI:10.1136/esmoopen-2019-000615; Conroy T., Castan F., Lopez A., Turpin A., Ben Abdelghani M., Wei A. C., et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022; 8 (11): 1571–8. DOI:10.1001/jamaoncol.2022.3829; Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364 (19): 1817–25. DOI:10.1056/NEJMoa1011923; Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358 (1): 36–46. DOI:10.1056/NEJMoa073149; Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A. C., Raoul J. L., et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018; 379 (25): 2395–406. DOI:10.1056/NEJMoa1809775; Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25 (15): 1960–6. DOI:10.1200/JCO.2006.07.9525; Рак поджелудочной железы: Клинические рекомендации (Одобрено на заседании научно-практического совета Министерства здравоохранения Российской Федерации (протокол № 032-3-4 от 12. 03. 2021). Рубрикатор клинических рекомендаций [Интернет]. М.; 2021. URL: https://cr.minzdrav.gov.ru/schema/355_4 (дата обращения: 02. 05. 2023).; Покатаев И. А., Гладков О. А., Загайнов В. Е., Кудашкин Н. Е., Кучин Д. М., Лядов В. К. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли. 2022; 12 (3s2-1): 530–44. DOI:10.18027/2224-5057-2022-12-3s2-530-544; Ducreux M., Cuhna A. S., Caramella C., Hollebecque A., Burtin P., Goéré D., et al. Cancer of the pancreas: ESMO Clinical Practice Guide-lines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v56–68. DOI:10.1093/annonc/mdv295; Pancreatic Adenocarcinoma Version 1.2032. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) [Internet]. Plymouth; 2022. [cited 2023 May 02] Available from: https://www.researchandmarkets.com/reports/5525422/pancreatic-adenocarcinoma-epidemiology; Hammel P., Huguet F., van Laethem J. L., Goldstein D., Glimelius B., Artru P., et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial. JAMA. 2016; 315 (17): 1844–53. DOI:10.1001/jama.2016.4324; Zarkavelis G., Amylidi A. L., Verbaanderd C., Cherny N. I., Metaxas Y., de Vries E. G. E., et al. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 2023; 8 (1): 100604. DOI:10.1016/j.esmoop.2022.100604; Upadhyay V. A., Johnson B. E., Landman A. B., Hassett M. J. Real-world analysis of off-label use of molecularly targeted therapy in a large academic medical center cohort. JCO Precis Oncol. 2022; 6: e2100232. DOI:10.1200/PO.21.00232; Lim M., Shulman D. S., Roberts H., Li A., Clymer J., Bona K., et al. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020; 9 (18): 6658–66. DOI:10.1002/cam4.3349; Aguilera D., Mazewski C., Fangusaro J., MacDonald T. J., McNall-Knapp R. Y., Hayes L. L., et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013; 29 (4): 589–96. DOI:10.1007/s00381-012-2013-4; Spini A., Ciccone V., Rosellini P., Ziche M., Lucenteforte E., Salvo F., et al. Safety of anti-angiogenic drugs in pediatric patients with solid tumors: a systematic review and meta-analysis. Cancers (Basel). 2022; 14 (21): 5315. DOI:10.3390/cancers14215315; Gururangan S., Fangusaro J., Poussaint T. Y., McLendon R. E., Onar-Thomas A., Wu S., et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas — a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014; 16 (2): 310–7. DOI:10.1093/neuonc/not154; Hwang E. I., Jakacki R. I., Fisher M. J., Kilburn L. B., Horn M., Vezina G., et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013; 60 (5): 776–82. DOI:10.1002/pbc.24297; Kalra M., Heath J. A., Kellie S. J., Dalla Pozza L., Stevens M. M., Swamy S., et al. Confi rmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma. J Pediatr Hematol Oncol. 2015; 37 (6): e341–6. DOI:10.1097/MPH.0000000000000371; Calò P., Pianton N., Basle A., Vasiljevic A., Barritault M., Beuriat P. A., et al. Bevacizumab as single agent in children and teenagers with optic pathway glioma. Cancers (Basel). 2023; 15 (4): 1036. DOI:10.3390/cancers15041036; Bennebroek C. A. M., van Zwol J., Porro G. L., Oostenbrink R., Dittrich A. T. M., Groot A. L. W., et al. Impact of bevacizumab on visual function, tumor size, and toxicity in pediatric progressive optic pathway glioma: A Retrospective Nationwide Multicentre Study. Cancers (Basel). 2022; 14(24):6087. DOI:10.3390/cancers14246087; Green K., Panagopoulou P., D’Arco F., O’Hare P., Bowman R., Walters B., et al. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes. Neuro Oncol. 2023; 25 (4): 774–85. DOI:10.1093/neuonc/noac223; Schmitt A. M., Walter M., Herbrand A. K., Jörger M., Moffa G., Novak U., et al. Characteristics and survival of patients with cancer with intended off-label use-a cohort study. BMJ Open. 2022; 12 (5): e060453. DOI:10.1136/bmjopen-2021-060453; Ladanie A., Schmitt A. M., Speich B., Naudet F., Agarwal A., Pereira T. V., et al. Clinical trial evidence supporting US food and drug administration approval of novel cancer therapies between 2000 and 2016. JAMA Netw Open. 2020; 3 (11): e2024406. DOI:10.1001/jamanetworkopen.2020.24406; Salas-Vega S., Iliopoulos O., Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017; 3: 382–90. DOI:10.1001/jamaoncol.2016.4166; Alabaku O., Laffey T. N., Suh K., Li M. Trends in endpoint use in pivotal trials and effi cacy for US Food and Drug Administrationapproved solid tumor therapies, 1995–2021. J Manag Care Spec Pharm. 2022; 28 (11): 1219–23. DOI:10.18553/jmcp.2022.28.11.1219; He Q., Li Q., Lv F., Kaitin K.I., Shao L. A survey of survival outcomes for targeted cancer drugs approved by the US food and drug administration. Ther Innov Regul Sci. 2021; 55 (4): 676–84. DOI:10.1007/s43441-021-00264-1; Conti R. M., Bernstein A. C., Villaflor V. M., Schilsky R. L., Rosenthal M. B., Bach P. B. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013; 31 (9): 1134–9. DOI:10.1200/JCO.2012.42.7252; van Waalwijk van Doorn-Khosrovani S. B., Pisters-van Roy A., van Saase L., van der Graaff M., Gijzen J., Sleijfer S., et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019; 30 (5): 663–5. DOI:10.1093/annonc/mdz119; Hoefflin R., Lazarou A., Hess M. E., Reiser M., Wehrle J., Metzger P., et al. Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers (Basel). 2021; 13 (5): 1151. DOI:10.3390/cancers13051151; https://www.surgonco.ru/jour/article/view/812

الاتاحة: https://www.surgonco.ru/jour/article/view/812
https://doi.org/10.24060/2076-3093-2023-13-2-151-158

المؤلفون: E. V. Artamonova, V. V. Breder, L. Yu. Vladimirova, I. A. Demidova, E. N. Imyanitov, К. К. Laktionov, M. P. Matrosova, S. V. Orlov, E. О. Rodionov, D. D. Sakaeva, M. I. Sekacheva, A. V. Smolin, N. V. Fadeeva, M. L. Filipenko, Е. В. Артамонова, В. В. Бредер, Л. Ю. Владимирова, И. A. Демидова, Е. Н. Имянитов, К. К. Лактионов, М. П. Матросова, С. В. Орлов, Е. О. Родионов, Д. Д. Сакаева, М. И. Секачёва, А. В. Смолин, Н. В. Фадеева, М. Л. Филипенко

المساهمون: The article is published with research and medical support from Bayer JSC., Статья опубликована при научно-медицинской поддержке АО «Байер».

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2022); 50-56 ; Медицинский Совет; № 9 (2022); 50-56 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: немелкоклеточный рак легкого, larotrectinib, NGS (next generation sequencing), TRK inhibitors, non-small cell lung cancer, ларотректиниб, NGS (секвенирование нового поколения), TRK-ингибиторы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6916/6214; Cocco E., Scaltriti M., Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-747. https://doi.org/10.1038/s41571-018-0113-0.; Vaishnavi A., Le A.T., Doebele R.C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34. https://doi.org/10.1158/2159-8290.CD-14-0765.; Amatu A., Sartore-Bianchi A., Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. https://doi.org/10.1136/esmoopen-2015-000023.; Khotskaya Y.B., Holla V.R., Farago A.F., Shaw K.R.M., Meric-Bernstam F., Hong D.S. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58-66. https://doi.org/10.1016/j.pharmthera.2017.02.006.; Brodeur G.M., Minturn J.E., Ho R., Simpson A.M., Iyer R., Varela C.R. et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15(10):3244-3250. https://doi.org/10.1158/1078-0432.CCR-08-1815.; Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545-1564. https://doi.org/10.1098/rstb.2006.1894.; Valent A., Danglot G., Bernheim A. Mapping of the tyrosine kinase receptors trkA (NTRK1), trkB (NTRK2) and trkC (NTRK3) to human chromosomes 1q22, 9q22 and 15q25 by fluorescence in situ hybridization. Eur J Hum Genet. 1997;5(2):102-104. Available at: https://pubmed.ncbi.nlm.nih. gov/9195161/.; Pirker R., Herth F.J., Kerr K.M., Filipits M., Taron M., Gandara D. et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thor Oncol. 2010;5(10):1706-1713. https://doi.org/10.1097/JTO.0b013e3181f1c8de.; Kim S., Park C., Ji Y., Kim D.G., Bae H., van Vrancken M. et al. Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine. J Mol Diagn. 2017;19(1):137-146. https://doi.org/10.1016/j.jmoldx.2016.09.006.; Dumenil C., Massiani M.-A., Dumoulin J., Giraud V., Labrune S., Chinet T., Leprieur E.G. Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE. 2018;13(4):e0195945. https://doi.org/10.1371/journal.pone.0195945.; Costantini A., Corny J., Fallet V., Renet S., Friard S., Chouaid C. et al. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. ERJ Open Research. 2018;4(2):00120-2017. https://doi.org/10.1183/23120541.00120-2017.; Gatalica Z., Xiu J., Swensen J., Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147-153. https://doi.org/10.1038/s41379-018-0118-3.; Farago A.F., Taylor M.S., Doebele R.C., Zhu V.W., Kummar S., Spira A.I. et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018;2018:PO.18.00037. https://doi.org/10.1200/PO.18.00037.; Drilon A., Laetsch T.W., Kummar S., DuBois S.G., Lassen U.N., Demetri G.D. et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739. https://doi.org/10.1056/NEJMoa1714448.; Hong D.S., Shen L., van Tilburg C.M., Tan D.S.-W., Kummar S., Lin J.J. et al. Longterm efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer. J Clin Oncol. 2021;39(15_suppl):3108-3108. https://doi.org/10.1200/JCO.2021.39.15_suppl.3108.; Hong D.S., DuBois S.G., Kummar S., Farago A., Albert C.M., Rohrberg K.S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2021;21(4):531-540. https://doi.org/10.1016/S1470-2045(19)30856-3.; Laetsch T.W., DuBois S.G., Mascarenhas L., Turpin B., Federman N., Albert C.M. et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705-714. https://doi.org/10.1016/S1470-2045(18)30119-0.; Hyman D.M., Laetsch T.W., Kummar S., DuBois S.G., Farago A.F., Pappo A.S. et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35(18_suppl). https://doi.org/10.1200/jco.2017.35.18_suppl.lba2501.; Hyman D.M., van Tilburg C.M., Albert C.M., Tan D.S.W., Geoerger B., Farago A.F. et al. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol. 2019;30(5):v162-v163. https://doi.org/10.1093/annonc/mdz244.007.; McDermott R., van Tilburg C.M., Farago A.F., Kummar S., Tan D.S.W., Albert C.M. et al. Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Ann Oncol. 2020;31(4 Suppl.):S1101-S1102. https://doi.org/10.1016/j.annonc.2020.08.1347.; Mascarenhas L., Albert C., Pappo A., Geoerger B., Doz F., Federman N. et al. Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset Of Pediatric Patients With TRK Fusion Cancer. Ped Blood Canc. 2020;67(S4). https://doi.org/10.1002/pbc.28742.; https://www.med-sovet.pro/jour/article/view/6916

الاتاحة: https://www.med-sovet.pro/jour/article/view/6916
https://doi.org/10.21518/2079-701X-2022-16-9-50-56

المؤلفون: О. В. Сомонова, Э. А. Антух, А. В. Варданян, Е. Г. Громова, Б. И. Долгушин, А. Л. Елизарова, Д. Д. Сакаева, В. Ю. Сельчук, А. А. Трякин, В. А. Черкасов

المصدر: Malignant tumours; Том 12, № 3s2-2 (2022); 159-170 ; Злокачественные опухоли; Том 12, № 3s2-2 (2022); 159-170 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: прямые оральные антикоагулянты, тромбоэмболические осложнения, низкомолекулярные гепарины, гепарин натрия, фондапаринукс

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1071/767; https://www.malignanttumors.org/jour/article/view/1071

الاتاحة: https://www.malignanttumors.org/jour/article/view/1071
https://doi.org/10.18027/2224-5057-2022-12-3s2-159-170

المؤلفون: Д. Д. Сакаева, К. Е. Борисов, И. С. Булавина, Л. М. Когония, И. А. Курмуков, Р. В. Орлова, М. М. Шабаева

المصدر: Malignant tumours; Том 12, № 3s2-2 (2022); 55-63 ; Злокачественные опухоли; Том 12, № 3s2-2 (2022); 55-63 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: колониестимулирующие факторы, противоопухолевая терапия, нежелательное явление, фебрильная нейтропения, антибиотикотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1063/759; https://www.malignanttumors.org/jour/article/view/1063

الاتاحة: https://www.malignanttumors.org/jour/article/view/1063
https://doi.org/10.18027/2224-5057-2022-12-3s2-55-63

المؤلفون: Л. М. Когония, Г. А. Новиков, Р. В. Орлова, А. В. Сидоров, И. А. Королева, Д. Д. Сакаева

المصدر: Malignant tumours; Том 12, № 3s2-2 (2022); 182-202 ; Злокачественные опухоли; Том 12, № 3s2-2 (2022); 182-202 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: адъювантные средства, поддерживающая терапия, паллиативная медицина, хронический болевой синдром, анальгетики, опиоиды, нестероидные противовоспалительные препараты

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1073/769; https://www.malignanttumors.org/jour/article/view/1073

الاتاحة: https://www.malignanttumors.org/jour/article/view/1073
https://doi.org/10.18027/2224-5057-2022-12-3s2-182-202

المؤلفون: А. А. Трякин, Н. С. Бесова, Н. М. Волков, О. А. Гладков, В. В. Карасева, Д. Д. Сакаева, Н. В. Фадеева, М. Ю. Федянин

المصدر: Malignant tumours; Том 12, № 3s2-1 (2022); 27-40 ; Злокачественные опухоли; Том 12, № 3s2-1 (2022); 27-40 ; 2587-6813 ; 2224-5057

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1021/718; https://www.malignanttumors.org/jour/article/view/1021

الاتاحة: https://www.malignanttumors.org/jour/article/view/1021
https://doi.org/10.18027/2224-5057-2022-12-3s2-27-40

المؤلفون: В. А. Чубенко, М. Б. Бычков, Н. В. Деньгина, А. Е. Кузьминов, Д. Д. Сакаева, А. И. Семенова

المصدر: Malignant tumours; Том 12, № 3s2-1 (2022); 60-66 ; Злокачественные опухоли; Том 12, № 3s2-1 (2022); 60-66 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лучевая терапия, локализованный мелкоклеточный рак лег‑ кого, распространенный мелкоклеточный рак легкого, химиотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1023/720; https://www.malignanttumors.org/jour/article/view/1023

الاتاحة: https://www.malignanttumors.org/jour/article/view/1023
https://doi.org/10.18027/2224-5057-2022-12-3s2-60-66

المؤلفون: Д. Д. Сакаева, И. А. Курмуков, Р. В. Орлова, М. М. Шабаева

المصدر: Malignant tumours; Том 10, № 3s2-2 (2020); 45-51 ; Злокачественные опухоли; Том 10, № 3s2-2 (2020); 45-51 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: колониестимулирующие факторы, противоопухолевая терапия, нежелательное явление, фебрильная нейтропения, антибиотикотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/790/554; https://www.malignanttumors.org/jour/article/view/790

الاتاحة: https://www.malignanttumors.org/jour/article/view/790
https://doi.org/10.18027/2224-5057-2020-10-3s2-39

المؤلفون: М. Б. Бычков, А. Г. Абдуллаев, С. Г. Багрова, Т. Д. Барболина, Т. Н. Борисова, Л. Ю. Владимирова, Н. В. Деньгина, Е. В. Левченко, Д. Д. Сакаева

المصدر: Malignant tumours; Том 10, № 3s2-1 (2020); 66-78 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 66-78 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: асцит, канцерогенные факторы, факторы прогноза, химиотерапия, комбинированное лечение, опухолевые плевриты, тримодальная терапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/752/517; https://www.malignanttumors.org/jour/article/view/752

الاتاحة: https://www.malignanttumors.org/jour/article/view/752
https://doi.org/10.18027/2224-5057-2020-10-3s2-04

المؤلفون: В. А. Чубенко, М. Б. Бычков, Н. В. Деньгина, А. Е. Кузьминов, Д. Д. Сакаева, А. И. Семенова

المصدر: Malignant tumours; Том 10, № 3s2-1 (2020); 60-65 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 60-65 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: лучевая терапия, локализованный мелкоклеточный рак легкого, распространенный мелкоклеточный рак легкого, химиотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/751/516; https://www.malignanttumors.org/jour/article/view/751

الاتاحة: https://www.malignanttumors.org/jour/article/view/751
https://doi.org/10.18027/2224-5057-2020-10-3s2-03

المؤلفون: К. К. Лактионов, Е. В. Артамонова, В. В. Бредер, В. А. Горбунова, Ф. В. Моисеенко, Е. В. Реутова, Д. Д. Сакаева, А. В. Смолин, М. Д. Тер-Ованесов

المصدر: Malignant tumours; Том 10, № 3s2-1 (2020); 40-59 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 40-59 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: ROS1, аденокарцинома, неплоскоклеточный рак легкого, плоскоклеточный рак легкого, мутация EGFR, транслокация ALK

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/750/515; https://www.malignanttumors.org/jour/article/view/750

الاتاحة: https://www.malignanttumors.org/jour/article/view/750
https://doi.org/10.18027/2224-5057-2020-10-3s2-02